This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: Memorial Sloan Kettering Cancer Center, Harvard College. Active years: 2022-2026.
Company Filing History:
2 out of 617 
1 out of 3,069 
Years Active: 2022-2026
Title: Michael Kharas: Innovator in Cancer Treatment
Introduction
Michael Kharas is a notable inventor based in New York, NY (US). He has made significant contributions to the field of cancer research, particularly in the development of targeted therapies. With a total of 2 patents, Kharas is recognized for his innovative approaches to treating acute myeloid leukemia and other cancers.
Latest Patents
Kharas's latest patents include the development of 5-amino-2-piperidinon-3-yl-1-oxoisoindoline derivatives for the degradation of IKZF2 degraders. These compounds promote the targeted degradation of IKZF2, a protein linked to the pathology of certain cancers, including acute myeloid leukemia. Additionally, he has disclosed methods for treating or preventing leukemia by administering a therapeutically effective amount of agents that reduce the expression of synaptotagmin-binding, cytoplasmic RNA-interacting protein (SYNCRIP) in subjects diagnosed with or at risk for acute myeloid leukemia.
Career Highlights
Throughout his career, Kharas has worked with prestigious institutions such as Memorial Sloan Kettering Cancer Center and Harvard College. His work has been instrumental in advancing the understanding and treatment of hematological malignancies.
Collaborations
Kharas has collaborated with notable colleagues, including Ly Vu and Christina M Woo. Their combined expertise has contributed to the development of innovative cancer therapies.
Conclusion
Michael Kharas is a prominent inventor whose work in cancer treatment has the potential to significantly impact patient outcomes. His innovative patents and collaborations highlight his commitment to advancing medical science.